Relevant bibliographies by topics / ALK positive Lung Cancer

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'ALK positive Lung Cancer'

Author: Grafiati
Published: 2 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'ALK positive Lung Cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "ALK positive Lung Cancer"

1

International, Journal of Medical Science and Innovative Research (IJMSIR). "Synchronous Colon Cancer and ALK Positive Lung Cancer." International Journal of Medical Science and Innovative Research (IJMSIR) 9, no. 5 (2024): 37–41. https://doi.org/10.5281/zenodo.15430305.

Full text
Abstract:
<strong>Abstract</strong> We present a case of synchronous ALK positive lung cancer and colon cancer. Patient presented to the hospital for routine health checkup and was incidentally detected with both the cancers. Initially it was thought to be colon cancer with lung metastasis. IHC was done on the lung biopsy specimen which was positive for TTF1 and ALK mutation and negative for SATB2. Colon specimen was also reported as mucinous adenocarcinoma histopathologically but IHC was negative for ALK mutation. Hence the diagnosis of synchronous double malignancy was made. Both the cancers were loca
APA, Harvard, Vancouver, ISO, and other styles
2

Poudiougou, Abdoul Karim, Hamadoun Traoré, Faman Sano, et al. "Efficacy of Lorlatinib on Cerebral Metastases in the Management of Alk-Positive Lung Adenocarcinoma, Case Report." Scholars Journal of Medical Case Reports 13, no. 01 (2025): 139–43. https://doi.org/10.36347/sjmcr.2025.v13i01.031.

Full text
Abstract:
Bronchial cancers are the leading cause of brain metastases and, in the absence of treatment, the median survival time for patients with bronchial cancer complicated by symptomatic brain metastases is approximately one month. Genetic sequencing has radically changed the management of non-small cell lung cancer over the last few decades. Anaplastic lymphoma kinase (ALK) rearrangements are responsible for 3-7% of non-small cell lung cancers. Patients with ALK-positive non-small cell lung cancer have a particular phenotype compared with other non-small cell lung cancers: they are younger, non-smo
APA, Harvard, Vancouver, ISO, and other styles
3

Ni, Wenjie. "ALK-inhibiting drugs for ALK-positive NSCLC." Theoretical and Natural Science 74, no. 1 (2025): 177–82. https://doi.org/10.54254/2753-8818/2024.la19334.

Full text
Abstract:
Lung cancer has already been one of the major reasons of cancer-related deaths, with anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC)taking up about 5%. This type of tumor has a high rate of central nervous system metastasis and standard chemotherapy has limited effect to effectively control progression. ALK-targeted inhibitors (ALK-TKIs) have notably extended the lifespan of patients with ALK-positive NSCLC, and third-generation inhibitors, in particular, have made significant progress in overcoming drug resistance and increasing intracranial activity, with parti
APA, Harvard, Vancouver, ISO, and other styles
4

Shaw, Alice T., and Jeffrey A. Engelman. "ALKin Lung Cancer: Past, Present, and Future." Journal of Clinical Oncology 31, no. 8 (2013): 1105–11. http://dx.doi.org/10.1200/jco.2012.44.5353.

Full text
Abstract:
In 2007, scientists discovered that anaplastic lymphoma kinase (ALK) gene rearrangements are present in a small subset of non–small-cell lung cancers. ALK-positive cancers are highly sensitive to small-molecule ALK kinase inhibitors, such as crizotinib. Phase I and II studies of crizotinib in ALK-positive lung cancer demonstrated impressive activity and clinical benefit, leading to rapid US Food and Drug Administration approval in 2011. Although crizotinib induces remissions and extends the lives of patients, cures are not achieved as resistance to therapy develops. In this review, we will dis
APA, Harvard, Vancouver, ISO, and other styles
5

Girard, Nicolas. "Crizotinib in ALK-positive lung cancer." Lancet Oncology 13, no. 10 (2012): 962–63. http://dx.doi.org/10.1016/s1470-2045(12)70375-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kharagezov, D. A., Yu N. Lazutin, E. A. Mirzoyan, et al. "Modern treatment of ALK-positive non-small cell lung cancer." South Russian Journal of Cancer 3, no. 2 (2022): 41–51. http://dx.doi.org/10.37748/2686-9039-2022-3-2-5.

Full text
Abstract:
Lung cancer (LC) takes the first place in the structure of overall oncology in males. More than 1.8 million of new cases of lung cancer (LC) are registered each year worldwide. LC is the leading cause of cancer death in both developing and developed countries, and the 5 years survival rate is as low as 19 %. Many factors explain such unsatisfactory outcomes, including the LC diagnosis at an advanced stage, when the currently available treatments can rarely provide cure. Non-small cell lung cancer (NSCLC) with chromosomal rearrangement of anaplastic lymphoma kinase (ALK) is sensitive to targete
APA, Harvard, Vancouver, ISO, and other styles
7

Yamasaki, Masahiro, Naomi Saito, Yu Hada, et al. "Nivolumab Therapy for Synchronous ALK-Positive Lung Cancer and Gastric Cancer." Case Reports in Oncology 10, no. 1 (2017): 361–67. http://dx.doi.org/10.1159/000470830.

Full text
Abstract:
Nivolumab is an immune checkpoint inhibitor with demonstrated efficacy against several malignant tumors. Alterations in driver oncogenes such as EGFR and ALK are a poor prognostic factor in nivolumab therapy for non-small cell lung cancer (NSCLC), whereas a smoking history is a well-known, favorable prognostic factor. However, an efficacy of nivolumab therapy for multiple primary malignant tumors (MPMTs) has not been reported, and its efficacy for driver oncogene-positive NSCLC in smokers is unclear. Herein, we report the case of a patient with a history of heavy smoking who developed synchron
APA, Harvard, Vancouver, ISO, and other styles
8

McCusker, Michael G., Alessandro Russo, Katherine A. Scilla, Ranee Mehra, and Christian Rolfo. "How I treat ALK-positive non-small cell lung cancer." ESMO Open 4, Suppl 2 (2019): e000524. http://dx.doi.org/10.1136/esmoopen-2019-000524.

Full text
Abstract:
Since the discovery of anaplastic lymphocyte kinase (ALK) rearrangement in non-small cell lung cancer (NSCLC) and subsequent development of increasingly effective and central nervous system (CNS)-penetrant first-generation, second-generation and third-generation ALK tyrosine kinase inhibitors (TKIs), the landscape of resistance mechanisms and treatment decisions has become increasingly complex. Tissue and/or plasma-based molecular tests can identify not only the rearrangement proper but also common resistance mechanisms to guide decision-making for further lines of treatment. However, frequent
APA, Harvard, Vancouver, ISO, and other styles
9

Sharma, Janaki, Vipul Pareek, Huijie Liu, and Haiying Cheng. "Emerging treatment for ALK-positive lung cancer." Expert Opinion on Emerging Drugs 21, no. 2 (2016): 147–55. http://dx.doi.org/10.1080/14728214.2016.1183642.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Pop, Ovidiu Laurean, Claudia Teodora Judea Pusta, Camelia Liana Buhas, et al. "Anaplastic Lymphoma Kinase (ALK) Overexpression in Lung Cancer Biopsies - An 18 month study in north western Romania." Revista de Chimie 70, no. 7 (2019): 2690–93. http://dx.doi.org/10.37358/rc.19.7.7407.

Full text
Abstract:
Lung cancer is the first cause of death worldwide of oncological patients. Most of them are non-small cell lung cancer (NSCLC) and many of them are characterized by different molecular markers that allow the development of personalized treatments. Epithelial growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) are the most frequently tested genes in lung adenocarcinoma and other lung carcinomas with glandular component. The aim of our study is to evaluate the distribution of ALK gene mutation in lung cancer patient from North West part of Romania. We analysed a number of 289 lung
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "ALK positive Lung Cancer"

1

Takahashi, Tsuyoshi. "Clinicopathologic Features of Non-Small Cell Lung Cancer with EML4-ALK Fusion Gene." Kyoto University, 2010. http://hdl.handle.net/2433/120559.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Itchins, Malinda. "Investigating Resistance To Tyrosine Kinase Inhibitor Therapy In Alk Gene Rearranged Non-Small Cell Lung Cancer- From Bedside To Bench And Back." Thesis, University of Sydney, 2020. https://hdl.handle.net/2123/23392.

Full text
Abstract:
Since its discovery in 2007, ALK-rearranged non-small cell lung cancer (NSCLC) has emerged as a unique and highly heterogeneous rare subgroup of lung cancer, more often affecting the young, fit and pauci-smokers. With the introduction of ALK-inhibitor (ALKi) therapy, quality of life and survival has been revolutionised for those diagnosed with advanced disease. Newer generation ALKi therapies have further improved survival gains, whilst vitally protecting the brain, as ALK NSCLC has a predilection to metastasise to the brain. With several ALKi’s now in the clinic, and more in development, ho
APA, Harvard, Vancouver, ISO, and other styles
3

Recondo, Gonzalo. "Resistance Mechanisms to ALK Tyrosine Kinase Inhibitors (TKIs) in NSCLC." Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS248/document.

Full text
Abstract:
Les analyses moléculaires et la classification des adénocarcinomes bronchiques ont conduit au développement de thérapies ciblées sélectives visant à améliorer le contrôle de la maladie et la survie des patients. ALK (anaplastic lymphoma kinase) est un récepteur tyrosine kinase de la famille des récepteurs de l'insuline. Des réarrangements chromosomiques impliquant le domaine kinase d’ALK sont présents dans environ 3 à 6% des patients atteints d'un adénocarcinome bronchique. La protéine de fusion provoque une activation du domaine kinase de manière constitutive et indépendante du ligand. Lorlat
APA, Harvard, Vancouver, ISO, and other styles
4

Tsuji, Takahiro. "Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model." Kyoto University, 2019. http://hdl.handle.net/2433/242907.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Moti, Naushad. "ALK-positive anaplastic large cell lymphoma is propagated by cancer stem cells that potentially originate from an early haematopoietic progenitor." Thesis, University of Cambridge, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.610843.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Funazo, Tomoko. "Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer Due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model." Kyoto University, 2020. http://hdl.handle.net/2433/258997.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hirsch, Jameson K., Andrea R. Floyd, and Paul R. Duberstein. "Perceived Health in Lung Cancer Patients: The Role of Positive and Negative Affect." Digital Commons @ East Tennessee State University, 2012. https://dc.etsu.edu/etsu-works/684.

Full text
Abstract:
Purpose: To examine the association of affective experience and health-related quality of life in lung cancer patients, we hypothesized that negative affect would be positively, and positive affect would be negatively, associated with perceived health. Methods: A sample of 133 English-speaking lung cancer patients (33% female; mean age = 63.68 years old, SD = 9.37) completed a battery of self-report surveys. Results: Results of our secondary analysis indicate that trait negative affect was significantly associated with poor physical and social functioning, greater role limitations due to emoti
APA, Harvard, Vancouver, ISO, and other styles
8

Mattsson, Johanna. "An integrative strategy for targeted evaluation of biomarker expression in non-small cell lung cancer." Doctoral thesis, Uppsala universitet, Molekylär och morfologisk patologi, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-285844.

Full text
Abstract:
Despite improvements in therapy, the prognosis for non-small cell lung cancer (NSCLC) patients remains poor, and cure is only possible in localized tumors after surgical resection. A new generation of targeted cancer drugs has led to the expectation that lung cancer therapy can be significantly improved, but these drugs are today only an option in a small subset of NSCLC patients, and their effect is temporary. Therefore, the aim of this thesis was to characterize NSCLC in order to find new treatment targets and to evaluate biomarkers that further optimize therapy selection. In Paper I, the ex
APA, Harvard, Vancouver, ISO, and other styles
9

Pinot, Roussel Hélène. "Étude du microenvironnement immunitaire des tumeurs du poumon avec réarrangement ALK et rôle des lymphocytes résidents mémoires dans les tumeurs muqueuses (poumon, ORL)." Thesis, Sorbonne Paris Cité, 2016. http://www.theses.fr/2016USPCB086.

Full text
Abstract:
Les cancers du poumon se placent au quatrième rang des cancers tous sexes confondus et constituent la première cause de mortalité par cancer pour l’homme et la troisième chez la femme. Le pronostic est sombre avec une survie relative globale estimée à 43% à 1 an et 14% à 5 ans. Les adénocarcinomes, les carcinomes épidermoïdes et les carcinomes à grandes cellules selon la classification OMS 2015 correspondent à 85% de ces cancers. Les adénocarcinomes pulmonaires ont été scindés en de multiples entités grâce aux progrès des techniques de biologie moléculaire ayant permis d’identifier différentes
APA, Harvard, Vancouver, ISO, and other styles
10

Pailler, Emma. "Identification de biomarqueurs de sensibilité et de résistance aux inhibiteurs de tyrosine kinase dans les cellules tumorales circulantes de patients atteints de cancers bronchiques non à petites cellules - Cas des remaniements ALK et ROS1." Thesis, Université Paris-Saclay (ComUE), 2016. http://www.theses.fr/2016SACLS410/document.

Full text
Abstract:
Les cellules tumorales circulantes (CTC) représentent un large champ de recherche susceptible de fournir des informations tant cliniques que fondamentales. Les CTC proviennent de tumeurs primitives ou métastatiques et représentent une population hétérogène de cellules très rares dans le flux sanguin. Leur caractérisation moléculaire est un défi technologique qui requiert des méthodes très sensibles et spécifiques. Dans les cancers bronchiques non à petites cellules (CBNPC), les CTC ont un véritable intérêt car les biopsies tumorales ne permettent pas toujours de réaliser les analyses moléculai
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "ALK positive Lung Cancer"

1

Grant, Warren, and Martin Scott-Brown. Prevention of cancer. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0350.

Full text
Abstract:
In the UK, the four commonest cancers—lung cancer, breast cancer, colon cancer, and prostate cancer—result in around 62 000 deaths every year. Although deaths from cancer have fallen in the UK over the last 20 years, the UK still suffers from higher cancer death rates than many other countries in Western Europe. In 1999, the UK government produced a White Paper called Saving Lives: Our Healthier Nation that outlined a national target to reduce the death rate from cancer by at least 20% in people under 75 by 2010. The subsequent NHS Cancer Plan of 2000 designed a framework by which to achieve t
APA, Harvard, Vancouver, ISO, and other styles
2

Lee, Christoph I. Low-Dose CT Screening for Lung Cancer. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190223700.003.0044.

Full text
Abstract:
This chapter, found in the cancer screening and management section of the book, provides a succinct synopsis of a key study examining the efficacy of low-dose computed tomography screening for lung cancer. This summary outlines the study methodology and design, major results, limitations and criticisms, related studies and additional information, and clinical implications. The study showed that annual low-dose CT screening among high-risk individuals decreases lung cancer mortality. While the rate of false positives was nearly 3 times higher for those screened by low-dose CT compared to chest
APA, Harvard, Vancouver, ISO, and other styles
3

Pink Ribbon Pink Ribbon Colorists. F*ck Lung Cancer Coloring Book: 50 Self Affirming Quotes and Inspirational Mantras to Color While Fighting Cancer, Spreading Good Vibes and Staying Positive. Independently Published, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Preusser, Matthias, Gabriele Schackert, and Brigitta G. Baumert. Metastatic brain tumours. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199651870.003.0019.

Full text
Abstract:
Brain metastasis is a common clinical challenge in cancer patients, particularly those with lung cancer, breast cancer, and melanoma. The prognosis is poor, with median overall survival times measured in months for most patient populations. Established treatments include neurosurgical resection, radiotherapy (including stereotactic radiosurgery and stereotactic radiotherapy, whole-brain radiotherapy, and new radiation techniques), and supportive care measures. Recently, more and more targeted therapies such as EGFR inhibitors, HER2 antagonists, BRAF inhibitors, ALK inhibitors, and immune check
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "ALK positive Lung Cancer"

1

Gemma, Akihiko. "ALK Mutant." In Molecular Targeted Therapy of Lung Cancer. Springer Singapore, 2017. http://dx.doi.org/10.1007/978-981-10-2002-5_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ou, Sai-Hong Ignatius, and Keisuke Shirai. "Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer." In Lung Cancer and Personalized Medicine. Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-24223-1_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Mancini, Maicol, and Yosef Yarden. "Resistance of Lung Cancer to Kinase Inhibitors Specific to EGFR or ALK." In Resistance to Targeted Anti-Cancer Therapeutics. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-67932-7_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Goto, Hisatsugu, and Yasuhiko Nishioka. "ALK and Others: How Important Are ALK and Other Mutations in the Management of Lung Cancer?" In Respiratory Disease Series: Diagnostic Tools and Disease Managements. Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-10-8144-6_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Eaby-Sandy, Beth. "Nursing Considerations with ALK and ROS1 Inhibitors in NSCLC." In Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16550-5_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Frankel, Diane, Elise Kaspi, and Patrice Roll. "Immunocytochemical Detection of ALK and ROS1 Rearrangements in Lung Cancer Cytological Samples." In Methods in Molecular Biology. Springer US, 2021. http://dx.doi.org/10.1007/978-1-0716-1278-1_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kung, Pei-Pei, Ricky Anthony Jones, and Paul Richardson. "Crizotinib (Xalkori): The First-in-Class ALK/ROS Inhibitor for Non-small Cell Lung Cancer." In Innovative Drug Synthesis. John Wiley & Sons, Inc, 2015. http://dx.doi.org/10.1002/9781118819951.ch7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nishio, Mizuho. "Computer-Aided Diagnosis of Lung Nodules: Systems for Estimation of Lung Cancer Probability and False-Positive Reduction of Lung Nodule Detection." In Lung Imaging and CADx. CRC Press, 2019. http://dx.doi.org/10.1201/9780429055959-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Michellys, Pierre-Yves. "Ceritinib: A Potent ALK Inhibitor for the Treatment of Crizotinib-Resistant Non-Small Cell Lung Cancer Tumors." In Successful Drug Discovery. Wiley-VCH Verlag GmbH & Co. KGaA, 2018. http://dx.doi.org/10.1002/9783527808694.ch6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Cairns, John Alexander. "Assessing the Cost-Effectiveness of Molecular Targeted Therapies and Immune Checkpoint Inhibitors." In Human Perspectives in Health Sciences and Technology. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-92612-0_11.

Full text
Abstract:
AbstractMolecular targeted therapies and immune checkpoint inhibitors have in recent years been transforming the care of many cancer patients. This chapter compares twenty-one appraisals of molecular targeted therapies in non-small-cell lung cancer, comprising six EGFR-TK inhibitors (gefitinib, erlotinib, afatinib, necitumumab, osimertinib and dacomitinib), five ALK inhibitors (crizotinib, ceritinib, alectinib, brigatinib and lorlatinib) and two ROS1 inhibitors (crizotinib and entrectinib), with fifteen appraisals of checkpoint inhibitors used in the treatment of non-small-cell lung cancer com
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "ALK positive Lung Cancer"

1

Soda, M., S. Takada, K. Takeuchi, Y. Ishikawa, Y. Sugiyama, and H. Mano. "Analysis of a Mouse Model forEML4-ALK-Positive Lung Cancer." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a2693.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bargiela, N. Fernández, M. Mateos Salvador, T. Calleja Chuclá, et al. "4CPS-118 Long-term survival in alk positive lung cancer: a case report." In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.209.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sharma, R., M. Fatima, S. F. Naidoo, N. Sharma, and A. Kumar Singh. "Crizotinib Induced Bradycardia in a Patient With ALK Positive Non Small Cell Lung Cancer." In American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6589.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kim, Mi Young, Geum Ock Kim, Dong Hoon Shin, Tae Min Kim, and Jin-Soo Kim. "Abstract 759: Metformin enhances the benefit of ALK inhibitors in ALK translocation-positive non-small cell lung cancer cells." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-759.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Horn, Leora, Karen L. Reckamp, Sandip Patel, et al. "Abstract CT151: CNS activity of ensartinib in ALK-positive non-small cell lung cancer patients." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-ct151.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Li, Chunrong, Joseph G. Kern, Shyhmin Huang, Eric A. Armstrong, Lauryn R. Werner, and Paul M. Harari. "Abstract 2102A: Simultaneous targeting of EGFR and ALK in EML4-ALK positive lung cancer to inhibit tumor cell proliferation and migration." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-2102a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Salmeron Navas, FJ, S. Fenix-Caballero, C. Moreno-Ramos, M. Dominguez Cantero, EM Barreiro-Fernandez, and EJ Alegre-Del Rey. "1ISG-021 Indirect comparison of brigatinib versus alectinib in ALK positive non-small cell lung cancer." In 25th Anniversary EAHP Congress, Hospital Pharmacy 5.0 – the future of patient care, 23–28 March 2021. British Medical Journal Publishing Group, 2021. http://dx.doi.org/10.1136/ejhpharm-2021-eahpconf.2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Cho, Hyeong Jun, Sang-Yun Lee, Dong Woo Lee, Seung Joon Kim, and Chang Dong Yeo. "Exploration of anticancer drug response prediction model using patient derived organoids with ALK-positive lung cancer." In ERS International Congress 2023 abstracts. European Respiratory Society, 2023. http://dx.doi.org/10.1183/13993003.congress-2023.pa1706.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Li, Chunrong, Shyhmin Huang, Noah Walters, Eric A. Armstrong, and Paul M. Harari. "Abstract 856: Combination of crizotinib and radiation in the treatment of ALK-positive and cetuximab-resistant lung cancer." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-856.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Yu Hua, Su, Cheng Wen-Chien, and Tu Chih-Yen. "Assessing the Prognostic Significance of Baseline Liver Metastasis in ALK Fusion-Positive Metastatic Lung Cancer: A retrospective study." In ERS Congress 2024 abstracts. European Respiratory Society, 2024. http://dx.doi.org/10.1183/13993003.congress-2024.pa2419.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "ALK positive Lung Cancer"

1

Xing, Puyuan, Xuezhi Hao, Xin Zhang, and Junling Li. Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.3.0142.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zhao, Binghao, and Yan Han. Efficacy and safety of therapies for ALK-positive non-small cell lung cancer with brain metastasis: a Bayesian network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.1.0056.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lin, Kehai, Jie Lin, Kunpeng Du, et al. Smoking status in the first line treatment of advanced ALK-positive non-small cell lung cancer : a Bayesian network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.8.0009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Rankin, Nicole, Deborah McGregor, Candice Donnelly, et al. Lung cancer screening using low-dose computed tomography for high risk populations: Investigating effectiveness and screening program implementation considerations: An Evidence Check rapid review brokered by the Sax Institute (www.saxinstitute.org.au) for the Cancer Institute NSW. The Sax Institute, 2019. http://dx.doi.org/10.57022/clzt5093.

Full text
Abstract:
Background Lung cancer is the number one cause of cancer death worldwide.(1) It is the fifth most commonly diagnosed cancer in Australia (12,741 cases diagnosed in 2018) and the leading cause of cancer death.(2) The number of years of potential life lost to lung cancer in Australia is estimated to be 58,450, similar to that of colorectal and breast cancer combined.(3) While tobacco control strategies are most effective for disease prevention in the general population, early detection via low dose computed tomography (LDCT) screening in high-risk populations is a viable option for detecting asy
APA, Harvard, Vancouver, ISO, and other styles
5

Chen, Fangjun, Yihong Ni, Jin Zhang, Yang Hao, Zhoujunyi Tian, and Guangliang Qiang. The value of Folate Receptor–Positive Circulating Tumor Cell as a diagnostic biomarker for lung cancer: a meta-analysis and system review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.7.0060.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kahwati, Leila, Matthew Avenarius, Leslie Brouwer, et al. Blood-Based Tests for Multiple Cancer Screening: A Systematic Review. AHRQ, 2025. https://doi.org/10.23970/ahrqepcsrmultiple.

Full text
Abstract:
Objectives. Screening for multiple cancers in a single blood test is potentially transformative. The objective of this review was to assess the benefits, harms, and accuracy of screening with blood-based multicancer screening tests (MCST) in asymptomatic adults. Data sources. Medline, Cochrane Library, trial registries, relevant government and commercial websites through December 2024; surveillance was conducted through March 31, 2025. Study Selection. Eligible designs included controlled studies for benefit outcomes (e.g., cancer mortality, cancer detection, quality of life), controlled and u
APA, Harvard, Vancouver, ISO, and other styles
7

Newman-Toker, David E., Susan M. Peterson, Shervin Badihian, et al. Diagnostic Errors in the Emergency Department: A Systematic Review. Agency for Healthcare Research and Quality (AHRQ), 2022. http://dx.doi.org/10.23970/ahrqepccer258.

Full text
Abstract:
Objectives. Diagnostic errors are a known patient safety concern across all clinical settings, including the emergency department (ED). We conducted a systematic review to determine the most frequent diseases and clinical presentations associated with diagnostic errors (and resulting harms) in the ED, measure error and harm frequency, as well as assess causal factors. Methods. We searched PubMed®, Cumulative Index to Nursing and Allied Health Literature (CINAHL®), and Embase® from January 2000 through September 2021. We included research studies and targeted grey literature reporting diagnosti
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'ALK positive Lung Cancer' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography